TOP TEN perturbations for 1555188_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1555188_at
Selected probe(set): 1555188_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1555188_at (1555188_at) across 6622 perturbations tested by GENEVESTIGATOR:

ovarian tumor study 16 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):1.9874983
Number of Samples:3 / 5
Experimental ovarian tumor study 16
Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue.

elesclomol study 2 / vehicle (DMSO) treated Hs 294T cell sample

Relative Expression (log2-ratio):1.8058128
Number of Samples:2 / 2
Experimental elesclomol study 2
Hs 294T cells (passage 11) treated with 100nM elesclomol at timepoint 6 hours. ATC code:---
Control vehicle (DMSO) treated Hs 294T cell sample
Hs 294T cells (passage 11) treated with 0.01% DMSO at timepoint 6 hours.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):-1.780613
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):-1.6642027
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

epigallocatechin gallate study 1 (45840ng/ml) / vehicle (DME) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):1.4525318
Number of Samples:3 / 17
Experimental epigallocatechin gallate study 1 (45840ng/ml)
Bronchial epithelial cells (NHBE) treated with epigallocatechin gallate (45840ng/ml; vendor: Santa Cruz / catalog number: sc-200802 / catalog name: (-)-Epigallocatechin Gallate) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). ATC code:---
Control vehicle (DME) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial).

diabetes type 2 study 27 (LCM) / diabetes type 2 study 27 (enzymatic)

Relative Expression (log2-ratio):1.2223368
Number of Samples:34 / 19
Experimental diabetes type 2 study 27 (LCM)
Pancreatic islet samples obtained from type 2 diabetic (T2D) phenotyped pancreatectomized patients (PPP) and isolated by laser capture microdissection (LCM). Islets specimens were retrieved by LCM from snap-frozen surgical specimen from patients who underwent pancreatectomy for pancreatic diseases. Histopathology of the resected tissue did not reveal insulitis in any PPP. Patients age <18 years were excluded. Patients with type 2 diabetes had fasting glycemia ≥7.0 mmol/l; HbA1C ≥6.5% and history of diabetes for >1 year.
Control diabetes type 2 study 27 (enzymatic)
Pancreatic islet samples obtained from type 2 diabetic (T2D) patients and isolated by enzymatic digestion. Well-preserved islets were isolated by collagenase digestion of pancreas from brain-dead organ donors which suffered from type 2 diabetes. After 2±1 days of culture, islets were successfully hand-picked and processed for further analyses. Type 2 diabetes was diagnosed based on clinical history, treatment with glucose-lowering drugs, and lack of anti-GAD65 autoantibodies.

ovarian tumor study 13 / ovarian tumor study 12

Relative Expression (log2-ratio):1.0941534
Number of Samples:18 / 6
Experimental ovarian tumor study 13
Human epithelial tumor cell samples from the ovary of patients with serous adenocarcinoma. Samples were derived by laser capture microdissection (LCM).
Control ovarian tumor study 12
Human stromal tumor cell samples from the ovary of patients with serous adenocarcinoma. Samples were derived by laser capture microdissection (LCM).

Burkitt lymfoma study 4 (IKK2 inhibitor) / Burkitt lymfoma study 4 (control)

Relative Expression (log2-ratio):1.0772619
Number of Samples:3 / 5
Experimental Burkitt lymfoma study 4 (IKK2 inhibitor)
BL-2 cell line with activated B cell receptor (BCR) through αIgM treatment and isolated after IKK2 inhibition. A reduced expression of BCR.1 genes after BCR activation was observed and this activation led to a delayed entry to and progression of mitosis and defects in metaphase.
Control Burkitt lymfoma study 4 (control)
BL-2 cell line with activated B cell receptor (BCR) through αIgM treatment. A reduced expression of BCR.1 genes after BCR activation was observed and this activation led to a delayed entry to and progression of mitosis and defects in metaphase.

PMA study 5 / vehicle (DMSO) treated BxPC3 cell sample

Relative Expression (log2-ratio):1.017786
Number of Samples:3 / 3
Experimental PMA study 5
Human primary pancreas adenocarcinoma cell line BxPC3 treated with 1µM PMA (phorbol-12-myristate 13-acetate) for 4 hours. ATC code:---
Control vehicle (DMSO) treated BxPC3 cell sample
Human primary pancreas adenocarcinoma cell line BxPC3 treated with 0.1% vehicle DMSO for 4 hours.

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):-0.99717426
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.